ORIGINAL ARTICLE
Year : 2010 | Volume
: 2 | Issue : 8 | Page : 365--370
Nucleos(t)ide analogues treatment outcome in genotype B and C chronic hepatitis B
Myo Nyein Aung, Wattana Leowattana, Noppadon Tangpukdee, Chatporn Kittitrakul
Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Department of Pharmacology, University of Medicine Mandalay, Myanmar
Correspondence Address:
Myo Nyein Aung
Department of Pharmacology, University of Medicine, Mandalay, 30th street, between 73rd and 74th street block, Chan Aye Thar Zan 05071, Mandalay, Myanmar; or TB/HIV Research Foundation, 1050 Sathanpayaban Road, Muang District, Chiang Rai, Thailand 57000
Background : Hepatitis B genotypes influence the course and severity of the disease. Aim: To compare the treatment outcome of chronic hepatitis B genotype B and C patients after treating with nucleos(t)ide analogues for six months. Patients and Methods: Forty chronic hepatitis B patients attending the liver clinic of Hospital for Tropical diseases, Bangkok, were studied in retrospective cohort design. Six genotype B patients (15%) and thirty-four genotype C patients (85%) were treated. Serum hepatitis B viral load , serum alanine amino transferase level, HBeAg status and alpha-feto protein level were measured at the time of starting nucleos(t) analogues therapy, and six months later. Besides, achievement of undetectable viral load was assessed in patients with normal serum alanine amino transferase compared to patients with high serum alanine amino transferase level. Results: After six months of nucleos (t) analogues treatment, achievement of undetectable hepatitis B viral load was higher in genotype B patients (66.7%) than in genotype C patients (42.4%) (Relative Risk=1.57, 0.79-3.14). Biochemical remission, HBeAg seroconversion and tumor marker levels between the two groups were not significantly different. Moreover, achievement of undetectable hepatitis B viral load was significantly higher in normal alanine amino transferase level (75%) than in patients with high serum alanine amino transferase level (33.3%) on nucleos(t)ide analogue treatment (Relative Risk=2.25, 1.20- 4.20). Conclusion: Chronic hepatitis B treatment outcome between genotype B and C were not significantly different. Patients with normalized serum alanine amino transferase level tend to achieve undetectable viral load after nucleoside analogues treatment.
How to cite this article:
Aung MN, Leowattana W, Tangpukdee N, Kittitrakul C. Nucleos(t)ide analogues treatment outcome in genotype B and C chronic hepatitis B.North Am J Med Sci 2010;2:365-370
|
How to cite this URL:
Aung MN, Leowattana W, Tangpukdee N, Kittitrakul C. Nucleos(t)ide analogues treatment outcome in genotype B and C chronic hepatitis B. North Am J Med Sci [serial online] 2010 [cited 2023 Jun 1 ];2:365-370
Available from: https://www.najms.org/article.asp?issn=1947-2714;year=2010;volume=2;issue=8;spage=365;epage=370;aulast=Aung;type=0 |
|
